GVHD, Chronic
10
3
4
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
20.0%
2 terminated out of 10 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Improvement of Women's Health After Allogeneic Stem Cell Transplantation
Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
Electronic Database for the Follow up of the ATG_FamilyStudy